Aspira Women's Health Inc.

Aspira Women's Health Inc. discovers, develops, and sells noninvasive, AI-powered tests for diagnosing gynecologic diseases, beginning with ovarian cancer. The company aims to expand its focus to differentiate other gynecologic diseases not typically assessed by traditional non-invasive clinical procedures. It commercializes existing and new technology through both in-house and distributed channels. Aspira Women's Health raises public awareness about the diagnostic superiority of Ova1Plus compared to cancer antigen 125 ("CA-125") alone for women with adnexal masses, and the performance of its tests in detecting ovarian cancer risk across different racial populations. The company expands access to its tests for Medicaid patients and advocates for legislation and adoption of its technology in professional society guidelines. Its experience with gynecologists and healthcare providers, along with the historical adoption of its OvaSuite tests, drives growth as new products are introduced. The company owns and operates Aspira Labs, Inc., a research and commercial Clinical Laboratory Improvement Amendments of 1988 certified ("CLIA") laboratory in Texas. Its product pipeline focuses on endometriosis and ovarian cancer. For endometriosis, the company is developing a new non-invasive test to aid in diagnosis.